Pharma strategy notes
This page focuses on the strategic decisions that matter most for pharma and pharma-adjacent investor workflows.
Core decision problems
- Is the evidence base strong enough for progression versus deprioritisation?
- How does mechanism differentiation hold up in a crowded therapeutic area?
- Where do biomarker and line-of-therapy choices create durable advantage?
Practical approach
- Integrate target biology, disease associations, and known-drug context early.
- Stress-test assumptions with downside-focused diligence framing.
- Convert evidence into board- and investment-committee language.